Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > I asked several times and no response re what will happen

<< Previous

Bullboard Posts

Next >>

Post by edroseon Apr 24, 2020 9:31pm

156 Views

Post# 30952347

I asked several times and no response re what will happen

If kly doesn’t pay talent debt by May 15th. Our board including senior management REFUSE TO RELEASE DETAILS OF TERMS AND CONDITIONS OF EXTENDING DEBT TO TALENT ,ONE thing we do know kly had to give bassada an extra 13 million shares since our bosrd agreed to increase by 50% the debt owed to bassada

my fear is that our current bosrd and ceo haven’t done anything to raise money or find partner like gw pharma and if we go in default bassada may own kly. If that happens we must file suit shareholder oppression and we have sufficient information to see they have been planning this

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle